- Avicanna (TSX:AVCN) has completed its observational real-world evidence study of its RHO Phyto branded cannabigerol gel on patients with musculoskeletal pain and inflammation
- The study evaluated the efficacy of the gel containing 2 per cent cannabidiol and 1 per cent cannabigerol on conditions such as arthritis, osteoarthritis, rheumatoid arthritis, fibromyalgia and muscle and joint pain among others
- According to the study, improvements were made in symptoms and quality of life in patients with musculoskeletal pain and inflammation
- Shares of Avicanna are up 5.13 per cent to C$0.41 as of 10:32 am ET
Avicanna (TSX:AVCN) has completed an observational real-world evidence study of its RHO Phyto branded cannabigerol gel on patients with musculoskeletal pain and inflammation.
In a news release, the Toronto-based company stated the study evaluated efficacy reported by patients of the gel containing 2 per cent cannabidiol and 1 per cent cannabigerol transdermal gel on conditions such as arthritis, osteoarthritis, rheumatoid arthritis, fibromyalgia, muscle and joint pain, localized pain, muscular and structural injuries, and post-surgical pain.
Rouhgly 71 patients completed baseline testing as well as a follow up one month later that included demographic, medical history, medication use and two standardized symptom questionnaires.
“The preliminary result of this study is in line with the reported results of our products with Canadian patients providing valuable insight for our next stages of clinical development,” Karolina Urban, executive vice president of medical affairs at Avicanna, said in a statement. “In parallel, this will propel our efforts under medical cannabis or cosmetic legislation internationally.”
Study participants had an average age of 58, with 64 per cent of patients being women, who all had symptoms of chronic pain. Prior to the study, participants reported taking an average of 10 medications such as NSAIDs, opioids, antidepressants or skeletal muscle relaxants.
The CBG Transdermal Gel is a part of Avicanna’s RHO Phyto formulary of medical products which includes proprietary oral, sublingual, and topical products containing a range of cannabinoids.
Avicanna’s scientific platform commercializes more than 30 products across various market segments: medical cannabis and wellness Products (RHO Phyto); pharmaceutical pipeline and medical cannabis care platform (MyMedi.ca).
Shares of Avicanna Inc. (TSX:AVCN) are up 5.13 per cent to C$0.41 as of 10:32 am ET.
Join the discussion: Find out what everybody’s saying about this stock on the Avicanna Inc. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
